31
views
0
recommends
+1 Recommend
2 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Early COVID-19 First-Dose Vaccination Coverage Among Residents and Staff Members of Skilled Nursing Facilities Participating in the Pharmacy Partnership for Long-Term Care Program — United States, December 2020–January 2021

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Residents and staff members of long-term care facilities (LTCFs), because they live and work in congregate settings, are at increased risk for infection with SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19) ( 1 , 2 ). In particular, skilled nursing facilities (SNFs), LTCFs that provide skilled nursing care and rehabilitation services for persons with complex medical needs, have been documented settings of COVID-19 outbreaks ( 3 ). In addition, residents of LTCFs might be at increased risk for severe outcomes because of their advanced age or the presence of underlying chronic medical conditions ( 4 ). As a result, the Advisory Committee on Immunization Practices has recommended that residents and staff members of LTCFs be offered vaccination in the initial COVID-19 vaccine allocation phase (Phase 1a) in the United States ( 5 ). In December 2020, CDC launched the Pharmacy Partnership for Long-Term Care Program* to facilitate on-site vaccination of residents and staff members at enrolled LTCFs. To evaluate early receipt of vaccine during the first month of the program, the number of eligible residents and staff members in enrolled SNFs was estimated using resident census data from the National Healthcare Safety Network (NHSN † ) and staffing data from the Centers for Medicare & Medicaid Services (CMS) Payroll-Based Journal. § Among 11,460 SNFs with at least one vaccination clinic during the first month of the program (December 18, 2020–January 17, 2021), an estimated median of 77.8% of residents (interquartile range [IQR] = 61.3%– 93.1%) and a median of 37.5% (IQR = 23.2%– 56.8%) of staff members per facility received ≥1 dose of COVID-19 vaccine through the Pharmacy Partnership for Long-Term Care Program. The program achieved moderately high coverage among residents; however, continued development and implementation of focused communication and outreach strategies are needed to improve vaccination coverage among staff members in SNFs and other long-term care settings. The Pharmacy Partnership for Long-Term Care Program is a public-private partnership among CDC, CVS Pharmacy (https://www.cvs.com), Managed Health Care Associates, Inc. (https://www.mhainc.com/home), and Walgreens (https://www.walgreens.com) to provide on-site COVID-19 vaccination of residents and staff members at enrolled LTCFs in 54 jurisdictions (49 states, four cities, and one territory). ¶ These organizations report facility-level aggregate vaccine administration data to CDC through a web-based data platform. For this analysis, COVID-19 vaccine administration data were restricted to those from enrolled SNFs with a unique, valid CMS Certification Number (CCN) that had a vaccination clinic conducted on site during the first month of the program (December 18, 2020–January 17, 2021). The number of residents eligible for vaccination was estimated using the mean of NHSN weekly resident census counts for each facility during the weeks of December 14, 2020–January 17, 2021. Resident census data were available for 11,376 facilities; 60 (0.5%) facilities with missing data were excluded from analyses of resident vaccination, as were 24 (0.2%) facilities where the CCN was linked to NHSN reporting from multiple sites. The number of staff members eligible for vaccination was estimated using CMS Payroll-Based Journal counts of unique staff members for each facility during July–September (Quarter 3) 2020. Payroll data were available for 11,134 facilities; 326 (2.8%) facilities with missing data were excluded from analyses of staff member vaccination. To estimate vaccination coverage, vaccine administration data for residents and staff members were matched to denominators for these groups using the facility CCN. National vaccination estimates included all CMS-certified SNFs with available denominator data and at least one on-site clinic in the first month of the program across all participating jurisdictions. Jurisdiction-level estimates are shown only for jurisdictions where >50 CMS-certified SNFs had at least one on-site clinic in the first month of the program and denominator data were available; data for participating cities were combined with those of their respective states for jurisdiction-level estimates. No individual-level data were included in the data files provided to CDC. All analyses were performed using SAS statistical software (version 9.4; SAS Institute). This activity was reviewed by CDC and was conducted consistent with applicable federal law and CDC policy.** During December 18, 2020–January 17, 2021, among 12,702 CMS-certified SNFs enrolled in the Pharmacy Partnership for Long-Term Care Program, 11,460 (90.2%) had at least one on-site vaccination clinic conducted through the program. †† A total of 713,909 residents and 582,104 staff members received ≥1 COVID-19 vaccine doses. §§ Among 11,376 (99.3%) of these facilities with available resident census data, a median estimated 77.8% (IQR = 61.3%–93.1%) of residents were vaccinated; and among 11,134 (97.2%) facilities with available staff member payroll data, a median of 37.5% (IQR = 23.2%–56.8%) of staff members were vaccinated (Figure 1). Among the 54 participating jurisdictions, 40 states had >50 CMS-certified SNFs that conducted at least one on-site clinic during the first month of the program and had available denominator data; the median percentage of residents vaccinated by state ranged from 65.7% to >100% ¶¶ and of staff members, ranged from 19.4% to 67.4% (Figure 2). FIGURE 1 Estimated percentage* of residents † and staff members § at skilled nursing facilities ¶ enrolled in the Pharmacy Partnership for Long-Term Care Program who received ≥1 dose of COVID-19 vaccine — United States, December 18, 2020–January 17, 2021 Abbreviations: CMS = Centers for Medicare & Medicaid Services; COVID-19 = coronavirus disease 2019. * Vaccination coverage >100% (not shown) was estimated for residents in 2,118 (18.5%) facilities and for staff members in 559 (4.8%) facilities. Estimated vaccination coverage in excess of 100% might reflect resident and staff member turnover, other variation in denominator estimates, or errors in reported vaccine administration data. † n = 11,376 facilities. The number of residents eligible for vaccination was estimated using the mean of National Healthcare Safety Network weekly resident census counts for each facility during December 14, 2020–January 17, 2021. § n = 11,134 facilities. The number of staff members eligible for vaccination was estimated using CMS Payroll-Based Journal counts of unique staff members for each facility during July–September (Quarter 3) 2020. Vaccination estimates reflect staff members vaccinated through the Pharmacy Partnership for Long-Term Care Program; additional staff members might have been vaccinated through other programs. ¶ Includes facilities with a unique, valid CMS Certification Number and with at least one on-site clinic conducted through the Pharmacy Partnership for Long-Term Care Program during December 18, 2020–January 17, 2021. The figure consists of two bar charts showing the estimated percentage of residents and staff members at skilled nursing facilities enrolled in the Pharmacy Partnership for Long-Term Care Program who received ≥1 dose of COVID-19 vaccine in the United States during December 18, 2020–January 17, 2021. FIGURE 2 Estimated median percentage of residents* and staff members † at skilled nursing facilities § enrolled in the Pharmacy Partnership for Long-Term Care Program who received ≥1 dose of COVID-19 vaccine, by jurisdiction ¶ — United States, December 18, 2020–January 17, 2021 Abbreviations: CMS = Centers for Medicare & Medicaid Services; COVID-19 = coronavirus disease 2019. * n = 11,376 facilities. The number of residents eligible for vaccination was estimated using the mean of National Healthcare Safety Network weekly resident census counts for each facility during December 14, 2020–January 17, 2021. † n = 11,134 facilities. The number of staff members eligible for vaccination was estimated using CMS Payroll-Based Journal counts of unique staff members for each facility during July–September (Quarter 3) 2020. Vaccination estimates reflect staff members vaccinated through the Pharmacy Partnership for Long-Term Care Program; additional staff members might have been vaccinated through other programs. § Includes facilities with a unique, valid CMS Certification Number and with at least one on-site clinic conducted through the Pharmacy Partnership for Long-Term Care Program during December 18, 2020–January 17, 2021. ¶ Participating jurisdictions do not include West Virginia. Jurisdiction-level estimates are only presented for 40 states that had >50 CMS-certified skilled nursing facilities with a vaccination clinic conducted during December 18, 2020–January 17, 2021. Data for Chicago, New York City, and Philadelphia were combined with those of their respective states for jurisdiction-level estimates. Washington, DC, and Puerto Rico had ≤50 skilled nursing facilities with an on-site clinic and available data and are not shown. The figure consists of two maps of the United States showing the estimated percentage of residents and staff members at skilled nursing facilities enrolled in the Pharmacy Partnership for Long-Term Care Program who received ≥1 dose of COVID-19 vaccine, by jurisdiction, in the United States during December 18, 2020–January 17, 2021. Discussion The Pharmacy Partnership for Long-Term Care Program partners with pharmacy providers to manage the COVID-19 vaccination process, reducing the workload for SNF administrators and jurisdictional health departments by coordinating scheduling, vaccine cold chain management, patient counseling, and vaccine administration. In the first month of the program, more than one million SNF residents and staff members in CMS-certified SNFs received on-site COVID-19 vaccination, with moderately high coverage among residents. Considering the high COVID-19–associated morbidity and mortality in SNFs ( 1 , 2 ) and, particularly, the risk for severe disease among SNF residents ( 3 ), vaccination of this population is a public health priority. However, the lower percentage of staff members vaccinated raises concern about low coverage among a population at high risk for occupational exposure to SARS-CoV-2. Low vaccination coverage among staff members working in LTCFs has been previously described for influenza vaccination; during the 2017–18 influenza season, vaccination coverage among LTCF staff members was lower than that among other health care workers ( 6 ), and survey data suggest that hesitancy among this population could be associated with skepticism about influenza vaccine effectiveness and perceived low risk for virus transmission to themselves or others ( 7 ). Although efforts are ongoing to promote confidence in COVID-19 vaccination among health care workers, challenges persist. According to a survey conducted in October 2020, 37% of nurses stated that they were not confident that a COVID-19 vaccine would be safe and effective, and only 34% agreed that they would voluntarily receive a COVID-19 vaccine.*** Frequently cited reasons for vaccine hesitancy included the perceived rapidity of vaccine development; inadequate information received about vaccine safety, side effects, and administration; and skepticism regarding the clinical trials and vaccine approval processes. Similarly, survey data from December 2020 indicated that nearly one third (29%) of respondents who worked in a health care delivery setting expressed COVID-19 vaccine hesitancy, and updated estimates from January 2021 indicated that hesitancy persisted, with 28% of health care workers indicating a desire to delay receipt of vaccine until they had more information about safety and effectiveness. ††† Specifically among LTCF staff members, a November 2020 survey found that only 45% of respondents were willing to receive a COVID-19 vaccine immediately once available, and an additional 24% would consider it in the future; the most frequently identified reason for vaccine hesitancy was concern about side effects ( 8 ). High staff member turnover, staff members working in multiple facilities ( 9 ), and limited resources for staff member outreach and education ( 10 ) are also potential barriers to vaccination in LTCFs. Use of focused communication messages to increase COVID-19 vaccine confidence in health care personnel §§§ and specifically among LTCF staff members ¶¶¶ , including messages regarding the documented safety and efficacy of authorized COVID-19 vaccines, might help improve vaccination acceptance and coverage. Staff members serve as a trusted source of information for patients and residents; therefore particularly in LTCF settings where residents and staff members might be vaccinated simultaneously, increasing vaccine confidence among staff members might have additional benefits for promoting vaccination among residents. Because coverage varied among jurisdictions, lessons learned from jurisdictions or individual facilities with high coverage might provide insight into strategies that could be applied more broadly. The findings in this report are subject to at least four limitations. First, vaccination procedures for health care workers might have underestimated the percentage of staff members vaccinated. Some jurisdictions encouraged LTCF staff members to be vaccinated through other programs for health care worker vaccination (e.g., clinics conducted by health departments or hospitals); only staff members vaccinated on site through the Pharmacy Partnership for Long-Term Care Program were included in these staff member vaccination estimates. Allocations to pharmacies included adequate vaccine to cover all expected residents and staff members in each facility; however, vaccination of staff members might have been intentionally staggered by SNFs in accordance with CDC’s clinical considerations for health care providers, although staggering is emphasized for second doses in the 2-dose series.**** Similarly, scheduling of clinics could have posed challenges for staff members who worked on a shift schedule or worked at multiple facilities, or staff members might not have been available for vaccination around holidays falling within the time frame evaluated. Systematic data concerning these potential barriers were not recorded, and they require further study. Second, the number of residents and staff members eligible for vaccination at each facility was estimated using secondary data sources and was not determined in real time at each vaccination clinic. The most recent available CMS Payroll-Based Journal data were from July to September 2020 and might have differed from staffing during the time of vaccination clinics. Additional variation in facility occupancy and resident and staff member turnover during December 2020–January 2021 could affect the accuracy and precision of these denominator estimates. Third, these estimates only evaluated the first month of the program; vaccination coverage might have increased as subsequent clinics were conducted at each facility. Vaccination was only evaluated among CMS-certified SNFs because of the ability to match to secondary data sources using the facility CCN; these estimates might not be generalizable to all other LTCFs enrolled in the program (e.g., assisted living facilities and non-CMS certified facilities). Finally, no qualitative data were collected to determine motivators for vaccination or to document and characterize possible vaccine hesitancy suggested by the low percentage of staff members vaccinated. Data on COVID-19 vaccine administration and coverage are essential to evaluating and supporting vaccination efforts over time. Additional data collected for the duration of the Pharmacy Partnership for Long-Term Care Program will characterize the percentage of residents and staff members vaccinated over time, as well as the percentage who complete the 2-dose series. Vaccine administration data can also be used to assess the effects of vaccination on COVID-19 case rates and transmission in high-risk settings; additional data will be collected through the NHSN LTCF Component. †††† Communications resources developed to increase vaccine confidence among LTCF staff members can be employed for public health outreach, and strategies to address structural barriers, such as scheduling around shift work or provision of paid medical leave for possible postvaccination side effects, should be encouraged. Further studies should explore differential vaccination coverage by characteristics, including geographic location, sociodemographic factors, and facility size, as well as characterize barriers to vaccination of persons working in LTCFs; qualitative assessment of attitudes and beliefs might inform additional communication strategies to improve vaccine confidence and increase vaccination among LTCF staff members. Summary What is already known about this topic? Residents and staff members in long-term care facilities, particularly skilled nursing facilities (SNFs), are at increased risk for COVID-19–associated morbidity and mortality and have been prioritized for the first phase of vaccination in the United States. What is added by this report? Among 11,460 SNFs with at least one vaccination clinic conducted during the first month of the CDC Pharmacy Partnership for Long-Term Care Program, a median of 77.8% of residents and 37.5% of staff members received ≥1 vaccine dose through the program. What are the implications for public health practice? Barriers to SNF staff member vaccination need to be overcome with continued development and implementation of focused communication and outreach strategies to improve vaccination coverage.

          Related collections

          Most cited references9

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) — United States, February 12–March 16, 2020

          On March 18, 2020, this report was posted online as an MMWR Early Release. Globally, approximately 170,000 confirmed cases of coronavirus disease 2019 (COVID-19) caused by the 2019 novel coronavirus (SARS-CoV-2) have been reported, including an estimated 7,000 deaths in approximately 150 countries ( 1 ). On March 11, 2020, the World Health Organization declared the COVID-19 outbreak a pandemic ( 2 ). Data from China have indicated that older adults, particularly those with serious underlying health conditions, are at higher risk for severe COVID-19–associated illness and death than are younger persons ( 3 ). Although the majority of reported COVID-19 cases in China were mild (81%), approximately 80% of deaths occurred among adults aged ≥60 years; only one (0.1%) death occurred in a person aged ≤19 years ( 3 ). In this report, COVID-19 cases in the United States that occurred during February 12–March 16, 2020 and severity of disease (hospitalization, admission to intensive care unit [ICU], and death) were analyzed by age group. As of March 16, a total of 4,226 COVID-19 cases in the United States had been reported to CDC, with multiple cases reported among older adults living in long-term care facilities ( 4 ). Overall, 31% of cases, 45% of hospitalizations, 53% of ICU admissions, and 80% of deaths associated with COVID-19 were among adults aged ≥65 years with the highest percentage of severe outcomes among persons aged ≥85 years. In contrast, no ICU admissions or deaths were reported among persons aged ≤19 years. Similar to reports from other countries, this finding suggests that the risk for serious disease and death from COVID-19 is higher in older age groups. Data from cases reported from 49 states, the District of Columbia, and three U.S. territories ( 5 ) to CDC during February 12–March 16 were analyzed. Cases among persons repatriated to the United States from Wuhan, China and from Japan (including patients repatriated from cruise ships) were excluded. States and jurisdictions voluntarily reported data on laboratory-confirmed cases of COVID-19 using previously developed data collection forms ( 6 ). The cases described in this report include both COVID-19 cases confirmed by state or local public health laboratories as well as those with a positive test at the state or local public health laboratories and confirmation at CDC. No data on serious underlying health conditions were available. Data on these cases are preliminary and are missing for some key characteristics of interest, including hospitalization status (1,514), ICU admission (2,253), death (2,001), and age (386). Because of these missing data, the percentages of hospitalizations, ICU admissions, and deaths (case-fatality percentages) were estimated as a range. The lower bound of these percentages was estimated by using all cases within each age group as denominators. The corresponding upper bound of these percentages was estimated by using only cases with known information on each outcome as denominators. As of March 16, a total of 4,226 COVID-19 cases had been reported in the United States, with reports increasing to 500 or more cases per day beginning March 14 (Figure 1). Among 2,449 patients with known age, 6% were aged ≥85, 25% were aged 65–84 years, 18% each were aged 55–64 years and 45–54 years, and 29% were aged 20–44 years (Figure 2). Only 5% of cases occurred in persons aged 0–19 years. FIGURE 1 Number of new coronavirus disease 2019 (COVID-19) cases reported daily*,† (N = 4,226) — United States, February 12–March 16, 2020 * Includes both COVID-19 cases confirmed by state or local public health laboratories, as well as those testing positive at the state or local public health laboratories and confirmed at CDC. † Cases identified before February 28 were aggregated and reported during March 1–3. The figure is a histogram, an epidemiologic curve showing 4,226 coronavirus disease 2019 (COVID-19) cases, by date of case report, in the United States during February 12–March 16, 2020. Figure 2 Coronavirus disease 2019 (COVID-19) hospitalizations,* intensive care unit (ICU) admissions, † and deaths, § by age group — United States, February 12– March 16, 2020 * Hospitalization status missing or unknown for 1,514 cases. † ICU status missing or unknown for 2,253 cases. § Illness outcome or death missing or unknown for 2,001 cases. The figure is a bar chart showing the number of coronavirus disease 2019 (COVID-19) hospitalizations, intensive care unit admissions, and deaths, by age group, in the United States during February 12– March 16, 2020. Among 508 (12%) patients known to have been hospitalized, 9% were aged ≥85 years, 36% were aged 65–84 years, 17% were aged 55–64 years, 18% were 45–54 years, and 20% were aged 20–44 years. Less than 1% of hospitalizations were among persons aged ≤19 years (Figure 2). The percentage of persons hospitalized increased with age, from 2%–3% among persons aged ≤19 years, to ≥31% among adults aged ≥85 years. (Table). TABLE Hospitalization, intensive care unit (ICU) admission, and case–fatality percentages for reported COVID–19 cases, by age group —United States, February 12–March 16, 2020 Age group (yrs) (no. of cases) %* Hospitalization ICU admission Case-fatality 0–19 (123) 1.6–2.5 0 0 20–44 (705) 14.3–20.8 2.0–4.2 0.1–0.2 45–54 (429) 21.2–28.3 5.4–10.4 0.5–0.8 55–64 (429) 20.5–30.1 4.7–11.2 1.4–2.6 65–74 (409) 28.6–43.5 8.1–18.8 2.7–4.9 75–84 (210) 30.5–58.7 10.5–31.0 4.3–10.5 ≥85 (144) 31.3–70.3 6.3–29.0 10.4–27.3 Total (2,449) 20.7–31.4 4.9–11.5 1.8–3.4 * Lower bound of range = number of persons hospitalized, admitted to ICU, or who died among total in age group; upper bound of range = number of persons hospitalized, admitted to ICU, or who died among total in age group with known hospitalization status, ICU admission status, or death. Among 121 patients known to have been admitted to an ICU, 7% of cases were reported among adults ≥85 years, 46% among adults aged 65–84 years, 36% among adults aged 45–64 years, and 12% among adults aged 20–44 years (Figure 2). No ICU admissions were reported among persons aged ≤19 years. Percentages of ICU admissions were lowest among adults aged 20–44 years (2%–4%) and highest among adults aged 75–84 years (11%–31%) (Table). Among 44 cases with known outcome, 15 (34%) deaths were reported among adults aged ≥85 years, 20 (46%) among adults aged 65–84 years, and nine (20%) among adults aged 20–64 years. Case-fatality percentages increased with increasing age, from no deaths reported among persons aged ≤19 years to highest percentages (10%–27%) among adults aged ≥85 years (Table) (Figure 2). Discussion Since February 12, 4,226 COVID-19 cases were reported in the United States; 31% of cases, 45% of hospitalizations, 53% of ICU admissions, and 80% of deaths occurred among adults aged ≥65 years with the highest percentage of severe outcomes among persons aged ≥85 years. These findings are similar to data from China, which indicated >80% of deaths occurred among persons aged ≥60 years ( 3 ). These preliminary data also demonstrate that severe illness leading to hospitalization, including ICU admission and death, can occur in adults of any age with COVID-19. In contrast, persons aged ≤19 years appear to have milder COVID-19 illness, with almost no hospitalizations or deaths reported to date in the United States in this age group. Given the spread of COVID-19 in many U.S. communities, CDC continues to update current recommendations and develop new resources and guidance, including for adults aged ≥65 years as well as those involved in their care ( 7 , 8 ). Approximately 49 million U.S. persons are aged ≥65 years ( 9 ), and many of these adults, who are at risk for severe COVID-19–associated illness, might depend on services and support to maintain their health and independence. To prepare for potential COVID-19 illness among persons at high risk, family members and caregivers of older adults should know what medications they are taking and ensure that food and required medical supplies are available. Long-term care facilities should be particularly vigilant to prevent the introduction and spread of COVID-19 ( 10 ). In addition, clinicians who care for adults should be aware that COVID-19 can result in severe disease among persons of all ages. Persons with suspected or confirmed COVID-19 should monitor their symptoms and call their provider for guidance if symptoms worsen or seek emergency care for persistent severe symptoms. Additional guidance is available for health care providers on CDC’s website (https://www.cdc.gov/coronavirus/2019-nCoV/hcp/index.html). This report describes the current epidemiology of COVID-19 in the United States, using preliminary data. The findings in this report are subject to at least five limitations. First, data were missing for key variables of interest. Data on age and outcomes, including hospitalization, ICU admission, and death, were missing for 9%–53% of cases, which likely resulted in an underestimation of these outcomes. Second, further time for follow-up is needed to ascertain outcomes among active cases. Third, the initial approach to testing was to identify patients among those with travel histories or persons with more severe disease, and these data might overestimate the prevalence of severe disease. Fourth, data on other risk factors, including serious underlying health conditions that could increase risk for complications and severe illness, were unavailable at the time of this analysis. Finally, limited testing to date underscores the importance of ongoing surveillance of COVID-19 cases. Additional investigation will increase the understanding about persons who are at risk for severe illness and death from COVID-19 and inform clinical guidance and community-based mitigation measures.* The risk for serious disease and death in COVID-19 cases among persons in the United States increases with age. Social distancing is recommended for all ages to slow the spread of the virus, protect the health care system, and help protect vulnerable older adults. Further, older adults should maintain adequate supplies of nonperishable foods and at least a 30-day supply of necessary medications, take precautions to keep space between themselves and others, stay away from those who are sick, avoid crowds as much as possible, avoid cruise travel and nonessential air travel, and stay home as much as possible to further reduce the risk of being exposed ( 7 ). Persons of all ages and communities can take actions to help slow the spread of COVID-19 and protect older adults. † Summary What is already known about this topic? Early data from China suggest that a majority of coronavirus disease 2019 (COVID-19) deaths have occurred among adults aged ≥60 years and among persons with serious underlying health conditions. What is added by this report? This first preliminary description of outcomes among patients with COVID-19 in the United States indicates that fatality was highest in persons aged ≥85, ranging from 10% to 27%, followed by 3% to 11% among persons aged 65–84 years, 1% to 3% among persons aged 55-64 years, <1% among persons aged 20–54 years, and no fatalities among persons aged ≤19 years. What are the implications for public health practice? COVID-19 can result in severe disease, including hospitalization, admission to an intensive care unit, and death, especially among older adults. Everyone can take actions, such as social distancing, to help slow the spread of COVID-19 and protect older adults from severe illness.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Epidemiology of Covid-19 in a Long-Term Care Facility in King County, Washington

            Abstract Background Long-term care facilities are high-risk settings for severe outcomes from outbreaks of Covid-19, owing to both the advanced age and frequent chronic underlying health conditions of the residents and the movement of health care personnel among facilities in a region. Methods After identification on February 28, 2020, of a confirmed case of Covid-19 in a skilled nursing facility in King County, Washington, Public Health–Seattle and King County, aided by the Centers for Disease Control and Prevention, launched a case investigation, contact tracing, quarantine of exposed persons, isolation of confirmed and suspected cases, and on-site enhancement of infection prevention and control. Results As of March 18, a total of 167 confirmed cases of Covid-19 affecting 101 residents, 50 health care personnel, and 16 visitors were found to be epidemiologically linked to the facility. Most cases among residents included respiratory illness consistent with Covid-19; however, in 7 residents no symptoms were documented. Hospitalization rates for facility residents, visitors, and staff were 54.5%, 50.0%, and 6.0%, respectively. The case fatality rate for residents was 33.7% (34 of 101). As of March 18, a total of 30 long-term care facilities with at least one confirmed case of Covid-19 had been identified in King County. Conclusions In the context of rapidly escalating Covid-19 outbreaks, proactive steps by long-term care facilities to identify and exclude potentially infected staff and visitors, actively monitor for potentially infected patients, and implement appropriate infection prevention and control measures are needed to prevent the introduction of Covid-19.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              The Advisory Committee on Immunization Practices’ Interim Recommendation for Allocating Initial Supplies of COVID-19 Vaccine — United States, 2020

              The emergence of SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), has led to a global pandemic that has disrupted all sectors of society. Less than 1 year after the SARS-CoV-2 genome was first sequenced, an application* for Emergency Use Authorization for a candidate vaccine has been filed with the Food and Drug Administration (FDA). However, even if one or more vaccine candidates receive authorization for emergency use, demand for COVID-19 vaccine is expected to exceed supply during the first months of the national vaccination program. The Advisory Committee on Immunization Practices (ACIP) advises CDC on population groups and circumstances for vaccine use. † ACIP convened on December 1, 2020, in advance of the completion of FDA’s review of the Emergency Use Authorization application, to provide interim guidance to federal, state, and local jurisdictions on allocation of initial doses of COVID-19 vaccine. ACIP recommended that, when a COVID-19 vaccine is authorized by FDA and recommended by ACIP, both 1) health care personnel § and 2) residents of long-term care facilities (LTCFs) ¶ be offered vaccination in the initial phase of the COVID-19 vaccination program (Phase 1a**). †† In its deliberations, ACIP considered scientific evidence of SARS-CoV-2 epidemiology, vaccination program implementation, and ethical principles. §§ The interim recommendation might be updated over the coming weeks based on additional safety and efficacy data from phase III clinical trials and conditions of FDA Emergency Use Authorization. Evidence-based information addressing COVID-19 vaccine topics including early allocation has been explicitly and transparently reviewed during seven public ACIP meetings ( 1 ). To inform policy options for ACIP, the COVID-19 Vaccines Work Group, comprising experts in vaccines and ethics, held more than 25 meetings to review data regarding vaccine candidates, COVID-19 surveillance, and modeling, as well as the vaccine allocation literature from published and external expert committee reports. Health care settings in general, and long-term care settings in particular, can be high-risk locations for SARS-CoV-2 exposure and transmission ( 2 – 4 ). Health care personnel are defined as paid and unpaid persons serving in health care settings who have the potential for direct or indirect exposure to patients or infectious materials. As of December 1, 2020, approximately 245,000 COVID-19 cases and 858 COVID-19-associated deaths had been reported among U.S. health care personnel ( 5 ). Early protection of health care personnel is critical to preserve capacity to care for patients with COVID-19 or other illnesses. LTCF residents are defined as adults who reside in facilities that provide a range of services, including medical and personal care, to persons who are unable to live independently. LTCF residents, because of their age, high rates of underlying medical conditions, and congregate living situation, are at high risk for infection and severe illness from COVID-19. As of November 15, 2020, approximately 500,000 COVID-19 cases and 70,000 associated deaths had been reported among residents of skilled nursing facilities, a subset of LTCFs serving residents with more complex medical needs ( 6 ). With respect to vaccination program implementation, vaccines that require cold and ultracold storage, specialized handling, and large minimum order requirements are most feasibly maintained in centralized vaccination clinics, such as acute health care settings, or through the federal Pharmacy Partnership for Long-term Care Program. ¶¶ ACIP’s ethical principles for allocating initial supplies of COVID-19 vaccine, namely to maximize benefits and minimize harms, promote justice, and mitigate health inequities ( 7 ), support the early vaccination of health care personnel and LTCF residents. Approximately 21 million U.S. health care personnel work in settings such as hospitals, LTCFs, outpatient clinics, home health care, public health clinical services, emergency medical services, and pharmacies. Health care personnel comprise clinical staff members, including nursing or medical assistants and support staff members (e.g., those who work in food, environmental, and administrative services) ( 8 ). Jurisdictions might consider first offering vaccine to health care personnel whose duties require proximity (within 6 feet) to other persons. If vaccine supply remains constrained, additional factors might be considered for subprioritization.*** Public health authorities and health care systems should work together to ensure COVID-19 vaccine access to health care personnel who are not affiliated with hospitals. Approximately 3 million adults reside in LTCFs, which include skilled nursing facilities, nursing homes, and assisted living facilities. Depending upon the number of initial vaccine doses available, jurisdictions might consider first offering vaccination to residents and health care personnel in skilled nursing facilities because of high medical acuity and COVID-19–associated mortality ( 6 ) among residents in these settings. Monitoring vaccine safety in all populations receiving COVID-19 vaccine is required under an Emergency Use Authorization. Vaccines are being studied in older adults with underlying health conditions; however, LTCF residents have not been specifically studied. ACIP members called for additional active safety monitoring in LTCFs to ensure timely reporting and evaluation of adverse events after immunization. ACIP will consider vaccine-specific recommendations and additional populations for vaccine allocation beyond Phase 1a when an FDA-authorized vaccine is available. Summary What is already known about this topic? Demand is expected to exceed supply during the first months of the national COVID-19 vaccination program. What is added by this report? The Advisory Committee on Immunization Practices (ACIP) recommended, as interim guidance, that both 1) health care personnel and 2) residents of long-term care facilities be offered COVID-19 vaccine in the initial phase of the vaccination program. What are the implications for public health practice? Federal, state, and local jurisdictions should use this guidance for COVID-19 vaccination program planning and implementation. ACIP will consider vaccine-specific recommendations and additional populations when a Food and Drug Administration–authorized vaccine is available.
                Bookmark

                Author and article information

                Journal
                MMWR Morb Mortal Wkly Rep
                MMWR Morb Mortal Wkly Rep
                WR
                Morbidity and Mortality Weekly Report
                Centers for Disease Control and Prevention
                0149-2195
                1545-861X
                05 February 2021
                05 February 2021
                : 70
                : 5
                : 178-182
                Affiliations
                CDC COVID-19 Response Team; American Health Care Association, Washington, DC; Palantir Technologies, Denver, Colorado; Centers for Medicare & Medicaid Services, Baltimore, Maryland; Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, CDC.
                Author notes
                Corresponding author: Radhika Gharpure, rgharpure@ 123456cdc.gov .
                Article
                mm7005e2
                10.15585/mmwr.mm7005e2
                7861479
                33539332
                cf05f6c5-99a4-405b-a8a5-e51d4ec1a5d8

                All material in the MMWR Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.

                History
                Categories
                Full Report

                Comments

                Comment on this article

                scite_

                Similar content17

                Cited by50

                Most referenced authors223